Tandem Diabetes Care, Inc. (TNDM) Revenue History
Annual and quarterly revenue from 2011 to present
TNDM Revenue Over Time (2011–2025)
TNDM Revenue Growth History
12 of 13 years with positive growth- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- +1072.1%
- FY2014 revenue growth
- +71.4%
- FY2015 revenue growth
- +46.5%
- FY2016 revenue growth
- +15.6%
- FY2017 revenue growth
- +27.7%
- FY2018 revenue growth
- +70.9%
- FY2019 revenue growth
- +97.0%
- FY2020 revenue growth
- +37.7%
- FY2021 revenue growth
- +40.9%
- FY2022 revenue growth
- +14.0%
- FY2023 revenue growth
- -6.7%
- FY2024 revenue growth
- +25.7%
- FY2025 revenue growth
- +7.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $247.2M | +5.5% |
| Q4 2025 | $290.4M | +2.7% |
| Q3 2025 | $249.3M | -31.4% |
| Q2 2025 | $240.7M | +8.5% |
| Q1 2025 | $234.4M | +22.3% |
| Q4 2024 | $282.6M | +43.6% |
| Q3 2024 | $363.3M | +95.7% |
| Q2 2024 | $221.9M | +13.3% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
TNDM's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
TNDM Revenue Analysis (2011–2025)
Current Revenue & Growth
As of June 21, 2026, Tandem Diabetes Care, Inc. (TNDM) generated trailing twelve-month (TTM) revenue of $1.03 billion, reflecting solid growth of +5.5% year-over-year. The most recent quarter (Q1 2026) recorded $247.2 million in revenue, down 14.9% sequentially.
Historical Growth Trajectory
TNDM's 5-year compound annual growth rate (CAGR) stands at +15.3%, indicating consistent double-digit revenue growth. The 3-year CAGR of +8.2% is below the 5-year average, signalling a growth deceleration in recent years. Tandem Diabetes Care, Inc.'s highest annual revenue of $1.01 billion was recorded in 2025, an all-time high.
Revenue by Segment
TNDM's revenue is primarily driven by Supplies and Other (54%), and Pump (46%). With over half of revenue concentrated in Supplies and Other, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including PODD (+31.9% YoY), DXCM (+16.2% YoY), and ABBV (+8.6% YoY) — TNDM has underperformed the peer group in revenue growth. Compare TNDM vs PODD →
TNDM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TNDMCurrent | $1.0B | +5.5% | +15.3% | -7.7% | |
 PODD | $2.7B | +31.9% | +24.5% | 17.5% | |
 DXCM | $4.7B | +16.2% | +19.3% | 19.6% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 MDT | $33.5B | +6.9% | +3.0% | 17.8% | |
 NVO | $309.1B | +8.1% | +19.5% | 41.3% |
TNDM Historical Revenue Data (2011–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.01B | +7.9% | $530.8M | 52.3% | $-78,122,000 | -7.7% |
| 2024 | $940.2M | +25.7% | $489.6M | 52.1% | $-99,127,000 | -10.5% |
| 2023 | $747.7M | -6.7% | $367.7M | 49.2% | $-233,230,000 | -31.2% |
| 2022 | $801.2M | +14.0% | $413.0M | 51.5% | $-92,848,000 | -11.6% |
| 2021 | $702.8M | +40.9% | $376.2M | 53.5% | $22.7M | 3.2% |
| 2020 | $498.8M | +37.7% | $260.5M | 52.2% | $-7,957,000 | -1.6% |
| 2019 | $362.3M | +97.0% | $194.2M | 53.6% | $-16,722,000 | -4.6% |
| 2018 | $183.9M | +70.9% | $89.8M | 48.9% | $-44,631,000 | -24.3% |
| 2017 | $107.6M | +27.7% | $44.1M | 41.0% | $-62,944,000 | -58.5% |
| 2016 | $84.2M | +15.6% | $23.6M | 28.0% | $-78,051,000 | -92.6% |
| 2015 | $72.8M | +46.5% | $26.6M | 36.5% | $-69,004,000 | -94.7% |
| 2014 | $49.7M | +71.4% | $15.2M | 30.7% | $-75,664,000 | -152.2% |
| 2013 | $29.0M | +1072.1% | $6.2M | 21.3% | $-49,434,000 | -170.4% |
| 2012 | $2.5M | - | $-1,348,252 | -54.5% | $-33,048,159 | -1335.4% |
| 2011 | $0 | - | $0 | - | $-24,211,709 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TNDM — Frequently Asked Questions
Quick answers to the most common questions about buying TNDM stock.
Is TNDM's revenue growth accelerating or slowing?
TNDM revenue growth is holding steady at +5.5% year-over-year. TTM revenue is $1.0B. The current growth rate closely tracks the 5-year CAGR of +15.3%, signalling consistent execution.
What is TNDM's revenue history from 2011 to 2026?
Tandem Diabetes Care, Inc. (TNDM) revenue history spans 2011 to 2026. TTM revenue as of 2026 is $1.0B, growing at +5.5% YoY. The 5-year CAGR is +15.3%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is TNDM's long-term revenue growth rate (CAGR)?
Tandem Diabetes Care, Inc.'s 5-year revenue CAGR of +15.3% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +5.5% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for TNDM.
Why does TNDM's quarterly revenue fluctuate?
TNDM quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Tandem Diabetes Care, Inc.'s revenue data from 2011 to 2026 shows full historical quarterly detail on this page.
How is TNDM's revenue distributed by segment?
TNDM reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does TNDM's revenue compare to industry peers?
Tandem Diabetes Care, Inc. (TNDM) with TTM revenue of $1.0B and +5.5% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.